Tag: DLBCL

Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among treated patients, all with diffuse large B-cell lymphoma (DLBCL) subtype Data on GC012F for treatment of relapsed/refractory multiple myeloma (RRMM) and donor-derived CAR-T GC007g for treatment of relapsed/refractory B-cell acute…

A new global, multicenter study is enrolling patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) to evaluate the efficacy and safety of epcoritamab plus standard chemotherapy. Researchers presented their plans for the study, called EPCORE DLBCL-2, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Standard treatment…

CNS Relapse Incidence and Survival Outcomes in Patients With High-Risk DLBCL Receiving High-Dose Methotrexate CNS Prophylaxis | PracticeUpdate …

Review . 2023 Jun;41(S1):107-111. doi: 10.1002/hon.3154. Affiliations Expand Affiliation 1 Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark. Item in Clipboard Review Martin Hutchings. Hematol Oncol. 2023 Jun. Show details Display options Display options Format AbstractPubMedPMID . 2023 Jun;41(S1):107-111. doi: 10.1002/hon.3154. Affiliation 1 Department of Haematology, Rigshospitalet, University…

Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only) June 12, 2023 (Issue: 1678) Epcoritamab-bysp (Epkinly – Genmab), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for subcutaneous treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise…more The Medical Letter is…

Tycel Phillips, MD, associate professor, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma and the potential impacts the drug’s recent approval will have in the community oncology setting. Transcript Can you describe…

GlobalData forecasts that the first-to-market advantage would propel Epkinly sales to $1.8 billion in 2029. Credit: CDC / Unsplash Genmab reported positive Phase I/II data for its bispecific antibody, which was developed in collaboration with AbbVie at the European Haematology Association (EHA). The open-label, multinational Phase I/II EPCORE NHL-2 trial…

The use of bone marrow (BM) biopsies may be unnecessary for the diagnostic workup of central nervous system (CNS) lymphomas with diffuse large B-cell lymphoma (DLBCL) histology if the patient’s positron emission tomography-computed tomography (PET-CT) scan is negative for lymphoma outside of the CNS, according to a Danish study published…

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The data are being presented in a poster today at the European…

ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The data are being presented in a poster today at the European Hematology Association 2023 Hybrid Congress (EHA2023) and will…

Oreofe O. Odejide, MD, MPH Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology. Patients with…

Media Release COPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) Results from…

COPENHAGEN, Denmark–(BUSINESS WIRE)– Genmab A/S (Nasdaq: GMAB) today announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide (R2) showed an overall response rate (ORR) of 98 percent and complete metabolic response (CMR) of 87 percent in…

Patients with depression, anxiety, or both in the 2 years before a diffuse large B-cell lymphoma (DLBCL) diagnosis have a worse prognosis, highlighting the need for a universal and systematic mental health screening for these patients, according to a study published in Lancet Haematology. The median age of patients when…

In healthy cells, pro- and anti-apoptotic BCL2 family and BH3-only proteins are expressed in a delicate equilibrium. In contrast, this homeostasis is frequently perturbed in cancer cells due to the overexpression of anti-apoptotic BCL2 family proteins. Variability in the expression and sequestration of these proteins in Diffuse Large B cell…

The development of new therapies and new technologies is leading to a better understanding of the immunology of diffuse large B-cell lymphoma (DLBCL), according to a new review. The article, published in the journal Cancers, outlines the latest insights and their implications for patient care. Corresponding author Taishi Takahara, MD,…

Combination atezolizumab, obinutuzumab, and venetoclax appears to produce durable responses in a subset of previously untreated patients with the diffuse large B-cell lymphoma variant of Richter syndrome (DLBCL-RS), according to research presented at the ASCO Annual Meeting 2023. For the open-label phase 2 MOLTO study (ClinicalTrials.gov Identifier: NCT04082897), researchers are…

The following is a summary of “Identification of a novel model based on ferroptosis-related genes for predicting the prognosis of diffuse large B-cell lymphomas,” published in the May 2023 issue of Hematology by Wang, et al. Diffuse large B-cell lymphomas (DLBCLs) are characterized by their phenotypic and genetic heterogeneity. For…

Background: Mental health disorders can potentially decrease quality of life and survival in patients with cancer. Little is known about the survival implications of mental health disorders in patients with diffuse large B-cell lymphoma (DLBCL). We aimed to evaluate the effect of pre-existing depression, anxiety, or both on survival in…

Among patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), early phase 2 trial data suggest that zilovertamab vedotin (ZV) may have antitumor activity, according to research presented at the ASCO Annual Meeting 2023. ZV is an antibody-drug conjugate that targets ROR1, a protein known to be expressed in…

New data presented at ASCO Annual Meeting 2023 suggest racial disparities may lead to increased risk of second primary malignancies (SPMs) among patients with diffuse large B-cell lymphoma (DLBCL) in the United States. Researchers explored a large-scale population-based database and found substantial disparities in SPM risk by race/ethnicity. Pragati Advani…

Introduction Primary testicular lymphoma, which accounts for less than 2% of non-Hodgkin lymphoma (NHL) cases, has similarities to extra-nodal NHL that occurs in immune-privileged sites, such as the eye and central nervous system (CNS).1 Pathologically, 80–90% of primary testicular lymphoma cases demonstrate diffuse large B-cell lymphoma (DLBCL) with non-germinal center/activated…

Source/Disclosures Published by: Source: Shah NN, et al. Abstract 7554. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Adaptive Biotechnology and a grant from the Froedtert Foundation supported this study. Shah reports consultant/advisory board roles with, research funding/paid expenses from or stock ownership in Adaptive…

The ASCO Post Staff Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival Narjust Florez, MD, of Dana-Farber Cancer Institute, and Filippo Gustavo Dall’Olio, MD, of Institut Gustave Roussy, discuss circulating tumor DNA tumor fraction, and its link to survival in…

Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that arises from malignant transformation of B lymphocytes. Outcome of patients with DLBCL has been significantly improved by rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, which is regarded “gold standard” of DLBCL therapy. It is unfortunate that febrile…

2023 ASCO Annual Meeting Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in…

Gastroenterology Research and Practice/ 2023/ Article/ Tab 1 / Research Article Table 1 Summary of the PEL cases diagnosed at KAUH and KFSH&RC, Jeddah. Age/sex Site Clinical presentation Diagnosis BM Tumor gross Follow-up (months) Treatment/outcome 1 68/M Lower esophagus Dysphagia and weight loss DLBCL −VE Polypoid mass 15 R-CHOP 2…

Asymptomatic patients with synchronous leptomeningeal involvement on baseline cerebrospinal fluid (CSF) examination are at elevated risk of further central nervous system (CNS) disease events and poor survival compared to patients without CSF involvement, according to a study published in the American Journal of Hematology. The study retrospectively identified adult patients with diffuse…

Although rare, patients should be monitored for thrombotic events while receiving chimeric antigen receptor (CAR) T-cell therapy, explain researchers of a new study published in International Journal of Molecular Sciences. The study, wrote the researchers, offers insight into emerging and uncommon complications following CAR T-cell therapy. To date, little has…

New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of choice for biopharma companies as evidenced in over a dozen investigational studies across multiple therapeutic approaches SEATTLE, June 02, 2023…

Gut microbial dysbiosis appears to play a role in the development of diffuse large B-cell lymphoma (DLBCL) and its responsiveness to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), according to research published in Blood. Enterobacteriaceae-family members also appear to be more abundant in patients with febrile neutropenia and those with…

Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023, highlighting the company’s commitment in rare haematological diseases. During the congress, Sobi will present important new data on haemophilia, immune thrombocytopenia, relapsed or refractory diffuse large b-cell lymphoma (DLBCL), and…

Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology. Patients with depression had the lowest survival,…

Thursday, June 29, 2023, 1:30 – 2:30 pm, Eastern Time Registrants can listen in live over the phone or online as a webcast. Our Panel of Experts David J. Straus, MD Hematology Oncologist, New York Cancer and Blood Specialists, Professor of Clinical Medicine, Weill Cornell Medical College Adolfo Enrique Diaz,…

doi: 10.1111/bjh.18900. Online ahead of print. Affiliations Expand Affiliations 1 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. 2 Stanford Cancer Institute, Stanford University, Stanford, California, USA. Item in Clipboard Michael Y He et al. Br J Haematol. 2023. Show details Display options Display options Format AbstractPubMedPMID doi: 10.1111/bjh.18900….

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward Details Category: DNA RNA and Cells Published on Thursday, 01 June 2023 10:51 Hits: 155 Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade…

Approval of the first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab-bysp (Epkinly) provides an effective alternative to chemotherapy for patients with diffuse large B cell lymphoma (DLBCL) in the third-line setting, according to Tycel Phillips, MD. On May 19, 2023, single-agent epcoritamab gained FDA approval for the treatment of patients with…

Polatuzumab vedotin-piiq in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) received endorsement from the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC). In an 11-2 vote, the committee decided in favor of the drug’s clinical benefit as treatment for previously untreated diffuse large B-cell lymphoma…

Acquired immune deficiency syndrome (AIDS)-related diffuse large B cell lymphoma (AR-DLBCL) is a rare disease with a high risk of mortality. There is no specific prognostic model for patients with AR-DLBCL. A total of 100 patients diagnosed with AR-DLBCL were enrolled in our study. Clinical features and prognostic factors for…

Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS (2012) High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 53(6):1113–1116. doi.org/10.3109/10428194.2011.639882 Article  PubMed  Google Scholar  Barrington SF,…

Microarray-based expression analysis and GEO database analysis The DLBCL-related miRNA expression profiles of GSE29493 and GSE40239 were retrieved from the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/). MiR-124’s pan cancer analysis is conducted through online websites (www.picb.ac.cn/dbDEMC/). Bioinformatics predicted NFATc1 as the target of miR-124-3p The miRbase (www.mirbase.org/), miRDB (mirdb.org), and…

%PDF-1.4 % 1 0 obj <> endobj 2 0 obj <>stream 2023-05-27T01:32:42 Adobe InDesign 15.1 (Windows) 2023-05-29T14:00:50+02:00 2023-05-29T14:00:50+02:00 Adobe PDF Library 15.0; modified using iText® 5.3.5 ©2000-2012 1T3XT BVBA (SPRINGER SBM; licensed version) Human bone marrow mesenchymal stem cells;DLBCL;Exosomes;MicroRNA-124-3p;NFATc1 False application/pdf doi.org/10.1186/s13287-023-03373-w BioMed Central Stem Cell Research & Therapy, doi.org/10.1186/s13287-023-03373-w…

Introduction Human immunodeficiency virus (HIV) infection is associated with an increased risk of hematological malignancy. Lymphoid neoplasms, particularly non-Hodgkin lymphoma, are the main hematologic malignancies that occur more frequently in connection with HIV infection non-Hodgkin lymphoma (NHL).1 Lymphomas are neoplastic lesions of the lymphoid system. According to World Health Organization…

Relapsed or Refractory Diffuse Large B-cell Lymphoma Market The relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2022 and is expected to exhibit a CAGR of 4.2% over the forecast period (2023-2030).” — Coherent Market Insights SEATTLE, WASHINGTON, INDIA, May…

Diffuse large B-cell lymphoma (DLBCL) is malignant hyperplasia of B lymphocytes and standard care cannot satisfactorily meet clinical needs. Potential diagnostic and prognostic DLBCL biomarkers are needed. NCBP1 could bind to the 5′-end cap of pre-mRNAs to participate in RNA processing, transcript nuclear export and translation. Aberrant NCBP1 expression is…

Editor’s note: This is an automatically generated transcript. Please notify hliptak@healio.com if there are concerns regarding accuracy of the transcription. It is important for patients, patient advocates, loved ones, as well as general oncologists seeing these patients in the community to be aware that the practice in 2023 is actually…

Editor’s note: This is an automatically generated transcript. Please notify hliptak@healio.com if there are concerns regarding accuracy of the transcription. Health disparities are a big problem across oncology and in lymphoma as well. One of the biggest issues we see with disparities is that not all patients get to a…

Editor’s note: This is an automatically generated transcript. Please notify hliptak@healio.com if there are concerns regarding accuracy of the transcription. Diffuse large B-cell lymphoma is the most common form of lymphoma, but despite very good frontline treatment, about a third of patients will have relapsed or refractory disease, meaning they…

Editor’s note: This is an automatically generated transcript. Please notify hliptak@healio.com if there are concerns regarding accuracy of the transcription. One is the cases of the patients who have, you know, are relatively young and fit, maybe in their fifties or sixties, and have really difficult-to-control lymphoma. In that case,…

Introduction Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25% of non-Hodgkin lymphoma (NHL), making it the most common subtype of this disease.1,2 DLBCL is an aggressive and heterogenous lymphoma, further subdivided into morphological and molecular variants with distinct clinical presentations that have varying prognoses and treatment choices.3 The initial…

F. Hoffmann-La Roche Ltd Basel, 26 May 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data…

Salles asks the committee how the treatment of patients with DLBCL varies in different countries, including the categorization of patients into various groups and what key factors are taken into consideration. The committee focus on the current use of clinical pathology for the diagnosis of subtypes and how this has…

Media Release COPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab–bysp in combination with rituximab–lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs exist Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating…

On May 25, 2023, Genmab, a prominent biotechnology company, will unveil several abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress. These presentations will center around epcoritamab, a subcutaneous bispecific antibody that addresses high unmet needs in lymphoma across multiple lines of…

DLBCL is a highly aggressive malignancy and is the most common type of non-Hodgkin lymphoma (NHL) worldwide. Credit: David A Litman via Shutterstock. AbbVie and Genmab have announced accelerated FDA approval for their bispecific T-cell engager (BiTE) Epkinly (epcoritamab-bysp) for the treatment of relapsed or refractory (R/R) diffuse large B-cell…

ReportLinker Report Highlights:. • Global Market Yearly & Quarterly Sales Insight (2018 Till Q1’2023). • Global Market Forecast Till 2028. • Global & Regional Sales Insights By Drugs (2018 Till Q1’2023). New York, May 25, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Bispecific Antibody Market…

Although several geriatric assessment tools are available to assess fitness of patients, these are not widely applied in routine practice. Comprehensive geriatric assessments such as CIRS-G are time consuming, often require a geriatrician, and are not validated to guide treatment. Furthermore, most of these historically used assessments are static and…

A spokesperson for Bayer said that a St. Louis County jury’s ruling on Tuesday in its favor was consistent with science. “The jury’s verdict in favor of the company brings this trial to a successful conclusion and is consistent with the evidence in this case that Roundup is not responsible…

Transcript: Andre H. Goy, MD: I want to go back to wrap up this conversation. In the second-line setting, now that we have multiple drugs approved, when you see a patient—I know we touched on this a little as we discussed every topic—summarize for our audience how to decide what…

Transcript: Andre H. Goy, MD: We cure a very large fraction of patients with large cell lymphoma, and CAR [chimeric antigen receptor] T-cell therapy now cures a fraction of the patients. In large cell lymphoma, we probably cure close to 40% with anti-CD19 CAR T-cell therapy. So as you mentioned,…

doi: 10.1111/cas.15856. Online ahead of print. Affiliations Expand Affiliations 1 Key Laboratory of Developmental Genes and Human Disease in Ministry of Education, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Biochemistry and Molecular Biology, Medical School of Southeast University, Nanjing, China. 2 Department of Pathology, Nanjing First Hospital,…

VJToday On May 19, 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the use of epcoritamab monotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBCL). Epcoritamab may be prescribed to patients with R/R DLBCL or HGBCL who…

A St. Louis County jury decided on Tuesday that a woman’s blood cancer was not caused by her use of Monsanto’s weed killer Roundup.  During the month-long trial, plaintiff attorneys for Sharlean Gordon maintained that the Roundup that she used at her Illinois residence was a toxin that had caused…

Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses the results from the EPCORE NHL-1 (NCT03625037), which recently led to the FDA approval of subcutaneous epcoritamab-bysp (Epkinly) for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after…

Researchers utilized a strategy of early lymphopheresis in a study aimed at optimizing CD19-based chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Results were reported in the British Journal of Haematology. In this prospective analysis, the investigators evaluated clinical outcomes in patients receiving…

Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has highlighted the clinical relevance of lymph node (LN) fibroblast and tumor-infiltrating lymphocyte (TIL) signatures within the tumor microenvironment (TME). However, the immunomodulatory role of fibroblasts in lymphoma remains unclear. Here, by studying human and mouse DLBCL-LNs, we identify the…

Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let’s have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be a threat to CAR-Ts, which already…

Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings NEWTON, Mass., May 23, 2023 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have…

Company Logo Dublin, May 23, 2023 (GLOBE NEWSWIRE) — The “Richter’s Syndrome – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com‘s offering. This report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Richter’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and…

An oncologist appearing as a defense expert witness for Monsanto told a jury on Monday that Plaintiff Sharlean Gordon’s cancer, which she alleges was caused by the use of weed killer Roundup, is cured and unlikely to recur. Plaintiff attorneys responded that Gordon’s suffering over 16 years could not be minimized….

Dublin, May 23, 2023 (GLOBE NEWSWIRE) — The “Richter’s Syndrome – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com‘s offering. This report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Richter’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage…

The U.S. Food and Drug Administration has granted accelerated approval for Genmab’s Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma. The recommended regimen consists of Epkinly administered subcutaneously in 28-day cycles until disease progression or unacceptable toxicity….

MONDAY, May 22, 2023 (HealthDay News) — The U.S. Food and Drug Administration has granted accelerated approval to Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma. The recommended regimen consists of Epkinly administered subcutaneously in 28-day cycles…

MONDAY, May 22, 2023 (HealthDay News) — The U.S. Food and Drug Administration has granted accelerated approval to Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma. The recommended regimen consists of Epkinly administered subcutaneously in 28-day cycles…

The approval was based on results from the Phase 1/2 EPCORE NHL-1 trial, which enrolled 157 patients with large B-cell lymphoma, which included 148 patients with DLBCL or high-grade B-cell lymphoma EPKINLY is a prescription medicine used to treat adults with certain types of DLBCL and HGBL patients. (Credit: AbbVie…

Epkinly is indicated to treat relapsed or refractory diffuse large B-cell lymphoma in adult patients. Credit: CoRus13/ commons.wikimedia.org. The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab‘s Epkinly (epcoritamab-bysp) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients. Epkinly has…

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin lymphoma worldwide. The emergence of multiple primary malignancies (MPMs) has been described as a new prognostic factor in many types of tumors. Methods: To investigate the morbidity, incidence, and survival of MPM in DLBCL, we retrospectively…

AbbVie and Genmab’s blood cancer therapy, Epkinly (epcoritamab-bysp), has been granted accelerated approval by the US Food and Drug Administration (FDA). The authorisation specifically applies to adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least two prior lines of treatment. DLBCL is the…

By The ASCO Post StaffPosted: 5/22/2023 10:21:00 AM Last Updated: 5/22/2023 11:17:07 AM On May 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific CD20-directed CD3 T-cell engager epcoritamab-bysp (Epkinly) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL…

AbbVie (ABBV Quick QuoteABBV – Free Report) and partner Genmab (GMAB Quick QuoteGMAB – Free Report) announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of…

AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of Epkinly.  Continued approval for this indication will be based on data…

Pictured: Front of FDA headquarters/Grandbrothers/Adobe Stock Friday, AbbVie and Genmab won the FDA’s greenlight for their bi-specific T-cell engager epcoritamab-bysp, now with the brand name Epkinly, for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. Epkinly was approved under the regulator’s accelerated pathway and is…

AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared as a treatment for diffuse large B-cell lymphoma (DLBCL). Epkinly (epcoritamab) is a CD20xCD3 bispecific and, according to its developers, is the “first and only” T-cell engager…

Prognostic Value of Prelymphodepletion Absolute Lymphocyte Counts in Relapsed/Refractory DLBCL Patients Treated With CAR-T Cells Here, study authors investigated the impact of pre-lymphodepletion absolute lymphocyte count on CAR-T cell therapy outcomes. Results demonstrated that pre-LD ALC may serve as a helpful indicator to predict the outcomes of CAR-T cell therapy…

The US Food and Drug Administration (FDA) on Friday approved Epkinly (epcoritamab-bysp), which is being is co-developed by US pharma major AbbVie (NYSE: ABBV) and Denmark’s Genmab (Nasdaq: GMAB) as part of the companies’ oncology collaboration, worth a potential $3.15 to the latter. AbbVie’s shares edged up 1.2% to $145.11…

FDA Approves Epkinly (epcoritamab-bysp) Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp), as the first and only T-cell…

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in challenging-to-treat R/R DLBCL patients EPKINLY represents the seventh approved medicine incorporating Genmab (NASDAQ:) innovation and third created via Genmab’s DuoBody® technology platform…

Expert Insights from Dr. Joshua Brody May 19, 2023 When it comes to managing DLBCL (Diffuse Large B-Cell Lymphoma), physical activity can play a crucial role in enhancing overall well-being. In this article, we delve into the valuable benefits of exercise for DLBCL patients and provide practical tips to help…

1. Introduction Diffuse large B-cell lymphoma (DLBCL) represents an aggressive subtype of Non-Hodgkin’s lymphomas (NHL) that accounts for approximately 40% of such tumours [1]. DLBCL is a highly heterogeneous disease that has an estimated 5-year survival of 69% in some studies [2]. The treatment is generally centred around the CHOP…

The FDA today approved the T-cell engaging bispecific antibody epcoritamab-bysp for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including those with DLBCL arising from indolent lymphoma or high-grade B-cell lymphoma. Epcoritamab, to be marketed as Epkinly, will be available…

The Food and Drug Administration (FDA) has granted accelerated approval to Epkinly™ (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after 2 or more lines of systemic therapy. Epcoritamab…

On May 19, 2023, EPKINLY (epcoritamab-bysp) was granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), after two or more lines…

The FDA has approved the first T-cell–engaging bispecific antibody, epcoritamab-bysp (Epkinly), for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBCL), after 2 or more lines of systemic therapies.1,2 It is recommended…

JHVEPhoto AbbVie (NYSE:ABBV) and Genmab A/S (GMAB) announced Friday that the FDA approved Epkinly, a bispecific antibody therapy, as a late-line option for adults with white blood cell cancer large B-cell lymphoma (DLBCL). Specifically, the FDA’s label for Epkinly allows its use following two or more lines of systemic therapy…

Action FDA has approved Epkinly (epcoritamab-bysp) injection for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma after two or more lines of systemic therapy. Epkinkly is injected subcutaneously (under the skin)…

The Food and Drug Administration (FDA) granted accelerated approval for Epkinly (epcoritamab-bysp) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval also includes patients with DLBCL occurring as a result of indolent lymphoma and high-grade B-cell lymphoma after two or more lines of…

The FDA granted approval to epcoritamab-bysp (Epkinly) as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, as well as DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma following 2 or more prior lines of therapy, according to a press release from the FDA.1…

The FDA has approved epcoritamab-bysp (Epkinly; AbbVie) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL) after 2 or more lines…

Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, discusses the recent approval of subcutaneous epcoritamab (Epkinly) for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy and its impact on the field. According to…

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later….